Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHS 114

Next Previous
Search
Drug Profile

CHS 114

Alternative Names: CHS-114; SRF-114

Latest Information Update: 09 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccinex
  • Developer Coherus BioSciences; Surface Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Dec 2024 Coherus Biosciences plans a phase Ib trial in Head and neck cancer and Gastric cancer (Combination therapy, Second-line therapy or greater) (Infusion), in Q1 2025
  • 24 Oct 2024 Coherus Biosciences plans a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) (Infusion), in March 2025 (NCT06657144)
  • 08 Sep 2024 Pharmacodynamics data from phase I trial in Solid tumours presented at the CRI-ENCI 8th Annual International Cancer, Immunotherapy Conference (CICON-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top